A multidimensional assessment of the burden of psoriasis: results from a multinational dermatologist and patient survey

Griffiths, Christopher E.M.; Jo, Seong Jin; Naldi, Luigi; Romiti, Ricardo; Guevara-Sanginés, Esther; Howe, T; Pietri, G.; Gilloteau, I.; Richardson, Craig; Tian, Haijun; Augustin, Matthias

doi:10.1111/bjd.16332

Cited by 73 publications

(88 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Plaque psoriasis is the most common form and is clinically characterized by well‐defined, raised, red and scaly plaques. In addition, a significant psychological burden, social stigmatization and increased risk of comorbidities may also be associated with the disease resulting in huge impact on patient well‐being . Treatment options for moderate to severe plaque psoriasis patients have expanded in recent years and now include systemic immune modulators for effective control.…”

Section: Introductionmentioning

confidence: 99%

Population pharmacokinetics of brodalumab in patients with moderate to severe plaque psoriasis

Timmermann

Hall

2019

Basic Clin Pharma Tox

View full text Add to dashboard Cite

Brodalumab is a fully human monoclonal antibody targeting the IL‐17 receptor A leading to an inhibition of the biological effect of IL‐17A, IL‐17F, IL‐17A/F heterodimer, IL‐17C and IL‐17E isoforms. It has shown to be efficacious in the treatment of moderate to severe plaque psoriasis (210 mg administered subcutaneously at weeks 0, 1 and 2 followed by 210 mg every 2 weeks [Q2W+1]). A population pharmacokinetic model based on psoriasis patients only from six clinical trials was developed to describe the pharmacokinetics and identify sources of variability. In patients with psoriasis, Brodalumab exhibits non‐linear pharmacokinetics due to target‐mediated drug disposition resulting in concentration‐dependent clearance. The pharmacokinetics was best described by a two‐compartment model with linear absorption and combined linear and Michaelis‐Menten elimination. The subcutaneous bioavailability of Brodalumab was 55%, absorption rate was 0.30 day−1, and body‐weight was found to affect the volume of distribution and clearance. For a reference patient with plaque psoriasis (body‐weight of 90 kg), the estimates were 0.16 L/d for linear serum clearance, 6.1 mg/d for the maximum non‐linear clearance rate, and 4.7 and 2.4 L for central and peripheral volume of distribution, respectively. For the approved dosing regimen, time to maximum concentration was 4 days and 90% of steady‐state was achieved after 10 weeks for a reference patient. Following last dose at steady‐state, 90% of the population of reference patients will reach serum concentrations below lower limit of quantification after 45 days.

show abstract

Section: Introductionmentioning

confidence: 99%

Population pharmacokinetics of brodalumab in patients with moderate to severe plaque psoriasis

Timmermann

Hall

2019

Basic Clin Pharma Tox

View full text Add to dashboard Cite

show abstract

“…Dear Editor , Psoriasis is an immune‐mediated inflammatory skin disease, with a prevalence of 0.09–11.4%, which affects approximately two million people in the U.K . It has a significant psychological and social impact on affected individuals, is associated with comorbidities such as depression, cardiovascular disease and inflammatory arthritis, and confers a substantial economic burden on the National Health Service . Access to appropriate care that addresses the high healthcare burden and complex interlinked physical, psychological and social needs of those who have psoriasis is often poor .…”

Section: Top 10 Priorities For Research In Psoriasis In Rank Order Omentioning

confidence: 99%

“…It has a significant psychological and social impact on affected individuals, is associated with comorbidities such as depression, cardiovascular disease and inflammatory arthritis, and confers a substantial economic burden on the National Health Service . Access to appropriate care that addresses the high healthcare burden and complex interlinked physical, psychological and social needs of those who have psoriasis is often poor . There remain many unmet needs and unanswered questions about psoriasis, which, if addressed by research, could improve clinical outcomes for patients.…”

Section: Top 10 Priorities For Research In Psoriasis In Rank Order Omentioning

confidence: 99%

The top 10 research priorities for psoriasis in the U.K.: results of a James Lind Alliance psoriasis Priority Setting Partnership

et al. 2019

Self Cite

View full text Add to dashboard Cite

“…Psoriasis is a chronic inflammatory skin disease which occurs worldwide with a high prevalence rate . It may have adverse impacts on the patient's physical functions and quality of life . Traditionally, the skin and joints were regarded to be the main organ systems affected by this disease.…”

Section: Introductionmentioning

confidence: 99%

Increased incidence of ischaemic heart disease and cerebrovascular disease in psoriasis patients with depression: a nationwide retrospective cohort study

Yuan

Chen

et al. 2019

Acad Dermatol Venereol

View full text Add to dashboard Cite

Background Psoriasis is known to confer a higher risk of cardiovascular and cerebrovascular diseases. However, very few studies have investigated whether the development of depression in psoriasis patients may further increase this vascular risk. Objective We investigated the risk of ischaemic heart disease and cerebrovascular disease in Taiwanese psoriasis patients with and without depression. Methods A nationwide population‐based retrospective cohort study was performed using the National Health Insurance Research Database. We included 604 psoriasis patients with depression, who were matched to 2416 psoriasis patients without depression (1 : 4 ratio). Relative risks (RR) with 95% confidence intervals (CI) were determined using the Cox proportional hazards regression model, with adjustment for demographic characteristics and comorbidities. Results Compared with psoriasis patients without depression, psoriasis patients with depression had greater risk of developing incident ischaemic heart disease (19.5% vs. 8.3%, adjusted RR 1.98, 95% CI 1.57–2.49), cerebrovascular disease (15.6% vs. 5.9%, adjusted RR 2.29, 95% CI 1.76–2.98), and either ischaemic heart disease or cerebrovascular disease (28.3% vs. 12.5%, adjusted RR 1.94, 95% CI 1.60–2.35). Subgroup analysis showed that in psoriasis patients with depression, a higher risk of incident ischaemic heart disease or cerebrovascular disease was present in age groups 30–100 years, in both males and females, and in both lower and higher income categories. Conclusion Depression is an independent risk factor for incident ischaemic heart disease and cerebrovascular disease in patients with psoriasis. Therefore, clinicians need to be vigilant for the increased vascular risk in psoriasis patients with depression.

show abstract

A multidimensional assessment of the burden of psoriasis: results from a multinational dermatologist and patient survey

Abstract: Psoriasis patients with physical and psychological comorbidities, itch and affected visible and sensitive body areas had lower QoL and greater work impairment compared to those without these conditions.

Cited by 73 publications

References 29 publications

Population pharmacokinetics of brodalumab in patients with moderate to severe plaque psoriasis

Population pharmacokinetics of brodalumab in patients with moderate to severe plaque psoriasis

The top 10 research priorities for psoriasis in the U.K.: results of a James Lind Alliance psoriasis Priority Setting Partnership

Increased incidence of ischaemic heart disease and cerebrovascular disease in psoriasis patients with depression: a nationwide retrospective cohort study

Contact Info

Product

Resources

About